Kymera Therapeutics, Inc.

Contributing Author

Recent Articles by Kymera Therapeutics, Inc.

Nov-04	Kymera Therapeutics Announces Third Quarter 2025 Financial Results and Provides a Business Update KYMR GlobeNewswire
Nov-03	Kymera Therapeutics to Participate in Upcoming November Investor Conferences KYMR GlobeNewswire
Oct-28	Kymera Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025 KYMR GlobeNewswire
Oct-27	Kymera Therapeutics Presents New Preclinical Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at the American College of Rheumatology Annual Meeting KYMR GlobeNewswire
Sep-17	Kymera Therapeutics Announces Late-Breaking Oral Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the European Academy of Dermatology & Venereology and European Respiratory Society Congresses KYMR GlobeNewswire
Sep-03	Kymera Therapeutics Appoints Brian Adams as Chief Legal Officer and Corporate Secretary KYMR GlobeNewswire
Aug-27	Kymera Therapeutics to Participate in Upcoming September Investor Conferences KYMR GlobeNewswire
Aug-11	Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update KYMR GlobeNewswire
Aug-04	Kymera Therapeutics to Report Second Quarter 2025 Financial Results on August 11, 2025 KYMR GlobeNewswire
Jun-26	Kymera Therapeutics Announces Pricing of $250 Million Public Offering KYMR GlobeNewswire
Jun-25	Kymera Therapeutics Announces Proposed Public Offering KYMR GlobeNewswire
Jun-25	Kymera Therapeutics Announces Sanofi IRAK4 Collaboration Update KYMR GlobeNewswire
Jun-02	Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Healthy Volunteer Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader KYMR GlobeNewswire
May-30	Kymera Therapeutics to Announce KT-621 Phase 1 Healthy Volunteer Trial Results on June 2, 2025 KYMR GlobeNewswire
May-29	Kymera Therapeutics to Participate in Upcoming June Investor Conferences KYMR GlobeNewswire
May-19	Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the American Thoracic Society International Conference KYMR GlobeNewswire
May-09	Kymera Therapeutics Expands Industry Leading Immunology Pipeline with New First-in-Class, Oral IRF5 Degrader Program with Potential to Address Multiple Immuno-Inflammatory Diseases KYMR GlobeNewswire
May-09	Kymera Therapeutics Announces First Quarter 2025 Financial Results and Provides a Business Update KYMR GlobeNewswire
May-07	Kymera Therapeutics to Participate in Fireside Chat at the BofA Securities 2025 Health Care Conference KYMR GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.